RGD Reference Report - Keratinocyte growth factor expression in hormone insensitive prostate cancer. - Rat Genome Database

RGD Reference Report - Keratinocyte growth factor expression in hormone insensitive prostate cancer. - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

General

Keratinocyte growth factor expression in hormone insensitive prostate cancer.
Authors:	Leung, HY Mehta, P Gray, LB Collins, AT Robson, CN Neal, DE
Citation:	Leung HY, etal., Oncogene. 1997 Aug 28;15(9):1115-20.
RGD ID:	2289086
Pubmed:	PMID:9285567 (View Abstract at PubMed)
DOI:	DOI:10.1038/sj.onc.1201256 (Journal Full-text)
Cellular interactions between stroma and epithelium are important in the growth and proliferation of prostate cancer. Peptide growth factors may facilitate the progression of prostate cancer as autocrine and/or paracrine factors. Keratinocyte Growth Factor (KGF or FGF7) has a differentiative and proliferative effect on the epithelium of the developing rat prostate. We investigated if KGF may act as a paracrine agent in human prostate cancer and examined the expression of KGF and Fibroblast Growth Factor Receptors (FGFRs) (IIIb and IIIc isoforms of the FGFR1 and FGFR2 genes). Sixty-five percent (11 out of 17 informative cases) of prostate cancers (CaP) expressed KGF mRNA by RT-PCR, while KGF expression was not detected in benign prostatic hyperplasia (BPH) (n = 6). Upregulation of KGF expression was related to hormone insensitive tumours (P<0.05). Tumour grade and stage were not associated with KGF expression. The source of KGF expression was further characterised using an in vitro primary culture model, showing its restriction to the prostatic stroma. The FGFR1IIIb isoform was expressed in all cases of prostate cancer (n = 17), and FGFR1IIIc mRNA was not detected. In the BPH group, FGFR1IIIb transcripts were detected in four out of six cases. FGFR2IIIb expression was detected in five of six cases of BPH and twelve out of seventeen (71%) cases of prostate cancer. In CaP, though not reaching statistical significance, the persistence of FGFR2IIIb expression appeared to be associated with hormone insensitive tumours (P=0.052). FGFR2IIIc expression was present in eleven of seventeen tumours but was absent in all six cases of BPH. Functional assessment of recombinant KGF in a proliferation assay demonstrated a mitogenic effect of up to 100% on cultured prostatic epithelial cells.

Only show annotations with direct experimental evidence (0 objects hidden)

Object Symbol	Species	Term	Qualifier	Evidence	With	Notes	Source	Original Reference(s)
FGF7	Human	prostate cancer		IEP		mRNA:increased expression:prostate gland stroma and hormone insensitive tumors	RGD
FGFR2	Human	prostate cancer		IEP		mRNA:increased expression:prostate gland	RGD
Fgf7	Rat	prostate cancer		ISO	FGF7 (Homo sapiens)		RGD
Fgf7	Mouse	prostate cancer		ISO	FGF7 (Homo sapiens)		RGD
Fgfr2	Rat	prostate cancer		ISO	FGFR2 (Homo sapiens)		RGD
Fgfr2	Mouse	prostate cancer		ISO	FGFR2 (Homo sapiens)		RGD
FGF7	Human	prostatic hypertrophy	no_association	IEP		mRNA:decreased expression:prostate gland	RGD
Fgf7	Mouse	prostatic hypertrophy	no_association	ISO	FGF7 (Homo sapiens)		RGD
Fgf7	Rat	prostatic hypertrophy	no_association	ISO	FGF7 (Homo sapiens)		RGD

Genes (Rattus norvegicus)


Fgf7 (fibroblast growth factor 7)	Fgfr2 (fibroblast growth factor receptor 2)

Genes (Mus musculus)


Fgf7 (fibroblast growth factor 7)	Fgfr2 (fibroblast growth factor receptor 2)

Genes (Homo sapiens)


FGF7 (fibroblast growth factor 7)	FGFR2 (fibroblast growth factor receptor 2)